Palatin Technologies, Inc.

–  Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy –  Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the …

Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference Read More »

 May 16, 2023, 07:30 ET  Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year …

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

 May 11, 2023, 16:15 ET  CRANBURY, N.J., May 11, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 Read More »

 May 09, 2023, 07:30 ET  –  Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease –  Clinical data confirms PL8177 oral formulation is delivered and contained in the colon –  Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J., May 9, 2023 /PRNewswire/ — Palatin Technologies, …

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference Read More »

 May 08, 2023, 16:04 ET  CRANBURY, N.J., May 8, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase …

Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar Read More »

 May 01, 2023, 16:00 ET  – Review of Phase 3 PL9643 Data for Dry Eye Disease – Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease – Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J., May 1, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: …

Palatin Technologies to Host Key Opinion Leader Webinar Read More »

 Apr 27, 2023, 07:30 ET  – Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease – Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile – Melody-1 Phase 3 clinical study continuing patient enrollment – final data …

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Read More »

 Apr 25, 2023, 07:30 ET  –  Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure –  Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J., April 25, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced …

Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma Read More »

 Apr 19, 2023, 07:30 ET  $3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J., April 19, 2023 …

Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results Read More »

 Apr 18, 2023, 07:30 ET  –  International Journal of Molecular Sciences manuscript demonstrates robust pre-clinical data in two retinal disease models –  Studies further demonstrate broad utility of melanocortin agonists in treating inflammatory conditions, especially in the eye CRANBURY, N.J., April 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that …

Pre-Clinical Data of Palatin’s Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences Read More »